RISK STRATIFICATION AND PATIENT COUNSELING FOR NATALIZUMAB IN MULTIPLE SCLEROSIS

被引：37

作者：

Fox, Robert J. ^{[1
]}

Rudick, Richard A.

机构：

[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

来源：

NEUROLOGY | 2012年 / 78卷 / 06期

基金：

美国国家卫生研究院;

关键词：

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

D O I：

10.1212/WNL.0b013e318245d2d0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：436 / 437

页数：2

共 7 条

[1]

Britt RR, ODDS DYING LIVESCIEN

[2] Anti-JC Virus Antibodies: Implications for PML Risk Stratification [J].

Gorelik, Leonid ;

Lerner, Michaela ;

Bixler, Sarah ;

Crossman, Mary ;

Schlain, Brian ;

Simon, Kenneth ;

Pace, Amy ;

Cheung, Anne ;

Chen, Ling Ling ;

Berman, Melissa ;

Zein, Fairuz ;

Wilson, Ewa ;

Yednock, Ted ;

Sandrock, Alfred ;

Goelz, Susan E. ;

Subramanyam, Meena .

ANNALS OF NEUROLOGY, 2010, 68 (03) :295-303

[3] Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists [J].

Heesen, Christoph ;

Kleiter, Ingo ;

Nguyen, Franziska ;

Schaeffler, Nina ;

Kasper, Juergen ;

Koepke, Sascha ;

Gaissmaier, Wolfgang .

MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) :1507-1512

[4]

Medical Information Biogen Idec, TYSABRI PML SAF UPD

[5]

Medical Information Biogen Idec, TYSABRI NAT SER ANT

[6] Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies? [J].

Tyler, Kenneth L. .

ANNALS OF NEUROLOGY, 2010, 68 (03) :271-274

[7] Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy [J].

Yousry, TA ;

Major, EO ;

Ryschkewitsch, C ;

Fahle, G ;

Fischer, S ;

Hou, J ;

Curfman, B ;

Miszkiel, K ;

Mueller-Lenke, N ;

Sanchez, E ;

Barkhof, F ;

Radue, EW ;

Jager, HR ;

Clifford, DB .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :924-933

← 1 →